Ocata Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

OCAT 6.73
price chart
Advanced Cell Technology Changes Name to Ocata Therapeutics
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc., (OTCBB: OCAT) today announced the change of its company name to Ocata Therapeutics, Inc., effective immediately. The change, which has been approved by the Company's ...
Related articles »  
The Butterfly Effect: Advanced Cell Technology Becomes Ocata Therapeutics ...
Ocata Therapeutics has entered an optimal moment in its developmental life cycle to initiate a long position. Prior to the as yet unknown date of up-list to the NASDAQ, which will occur with an accompanying equity raise, there is reason to believe the ...
Latest Updates on Ocata Therapeutics Inc (OTCMKTS:OCAT)  Equities Focus (registration)
Related articles »  
Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of regenerative ophthalmology therapeutics.
Ocata Therapeutics To Trade On Nasdaq Global Market: Can The Bulls Finally ...
After months, if not years for some, Ocata shareholders were pleasantly surprised by the after-hours filing of the Form 8-A on February 23, 2015 by Ocata Therapeutics (NASDAQ:OCAT), which provides for registration of certain classes of securities ...
Ocata Therapeutics Inc (OTCMKTS:OCAT) Is Rewarded With Two New Immune ...  Traders350
Ocata Therapeutics to Present at 2015 Cowen Health Care Conference  MarketWatch
Should you place a bet on Ocata Therapeutics?
This brings us to Ocata Therapeutics. The company calls itself a "leader in regenerative medicine." What is that, and on what basis is Advanced Cell a leader in this field?
Related articles »  
Ocata Therapeutics Announces Positive Results in Treating Macular ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced that a study has been published that includes top-line, positive results in ...
Stem cells pass safety test in vision-loss trial  Nature.com
Dr Robert Lanza, Chief Scientific Officer of Ocata Therapeutics to be a ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Robert Lanza, M.D.
Hot Watch List: Ocata Therapeutics, Inc. (NASDAQ:OCAT), Micron Technology ...
Ocata Therapeutics, Inc. (NASDAQ:OCAT) belongs to Healthcare sector. Its weekly performance is 6.77%. On last trading day company shares ended up $6.62.
Mid-Day Changers: Ocata Therapeutics, Inc. (OCAT), Biodel Inc. (BIOD), iPath ...
Ocata Therapeutics, Inc. (OCAT) of the Healthcare sector has changed by 3.54% and at noon is trading with a volume of 79,612 shares with a volatility this week of 3.28%.
Friday's Pre-Market Outlook: Opus Bank (OPB), Ocata Therapeutics, Inc. (OCAT ...
Ocata Therapeutics, Inc. (OCAT) of the Biotechnology sector closed out the day Thursday at $6.32, a loss of -1.25% with a return on investment of 1300.00% trading at a volume of 211,009 shares.